Fludarabine, cytarabine, and G‐CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
暂无分享,去创建一个
G Mele | R. Latagliata | F. Ferrara | V. Zagonel | A. Pinto | A. Tedeschi | M. Montillo | M C Petti | V Zagonel | M Montillo | S Mirto | R Latagliata | S Magrin | A Pinto | A Tedeschi | F Ferrara | M. Petti | S. Magrin | G. Mele | S. Mirto
[1] T. Lister,et al. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen‐year period , 1993, British journal of haematology.
[2] P. Zinzani,et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. , 1994, Leukemia.
[3] M. Andreeff,et al. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. , 1990, Leukemia.
[4] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[5] W. Hiddemann,et al. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. , 1990, Leukemia.
[6] E. Estey,et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Bennett,et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). , 1995, Blood.
[8] M A Boogaerts,et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Lazarus,et al. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Thall,et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Andreeff,et al. Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs. , 1994, Leukemia.
[12] F. Mandelli,et al. Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1996, Leukemia.
[13] P. Sonneveld,et al. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. , 1994, Leukemia.
[14] E. Estey,et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] O. Haas,et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia , 1996, Annals of Hematology.
[16] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[17] T. Nokes,et al. FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes. , 1997, Leukemia & lymphoma.
[18] R. Bouabdallah,et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.
[19] F. Mandelli,et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] E. Estey,et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. , 1993, Leukemia & lymphoma.
[21] G. Papa,et al. Results of a randomised, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia , 1995 .
[22] C. Bloomfield,et al. Clinical significance of cytogenetics in acute myeloid leukemia. , 1997, Seminars in oncology.
[23] F. Patrone,et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. , 1996, Haematologica.